Biosimilars in the management of neutropenia: focus on filgrastim

about

Biosimilars in the management of neutropenia: focus on filgrastim

Item

http://www.wikidata.org/entity/Q26764906

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Biosimilars in the management of neutropenia: focus on filgrastim

@ast

Biosimilars in the management of neutropenia: focus on filgrastim

@en

Biosimilars in the management of neutropenia: focus on filgrastim

@nl

type

Item

label

Biosimilars in the management of neutropenia: focus on filgrastim

@ast

Biosimilars in the management of neutropenia: focus on filgrastim

@en

Biosimilars in the management of neutropenia: focus on filgrastim

@nl

prefLabel

Biosimilars in the management of neutropenia: focus on filgrastim

@ast

Biosimilars in the management of neutropenia: focus on filgrastim

@en

Biosimilars in the management of neutropenia: focus on filgrastim

@nl

P1476

Biosimilars in the management of neutropenia: focus on filgrastim

@en

P2093

Désirée Caselli

http://www.w3.org/2001/XMLSchema#string

Maurizio Aricò

http://www.w3.org/2001/XMLSchema#string

P2860

Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma

Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner

Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry.

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis

Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study.

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

P304

17-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S73580

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Simone Cesaro

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

295082240

http://www.w3.org/2001/XMLSchema#string

P698

26937170

http://www.w3.org/2001/XMLSchema#string

P932

4762467

http://www.w3.org/2001/XMLSchema#string